Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol® Dispersing

Drug Development and Industrial Pharmacy

Volumn 36, Issue 9, 2010, Pages 1064-1078

  Dinunzio, James C ^a   Hughey, Justin R ^a   Brough, Chris ^b   Miller, Dave A ^a   Williams Iii, Robert O ^a   McGinity, James W ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b DisperSol Technologies LLC   (United States)

Author keywords

Bioavailability; Concentration enhancing polymers; Hydroxypropyl methylcellulose acetate succinate; Itraconazole; Solid dispersion; Supersaturation; Thermal processing

Indexed keywords

DISPERSANT; ITRACONAZOLE; OXIDIZED CELLULOSE; POLYMER;

ANIMAL MODEL; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; IONIZATION; MOLECULAR WEIGHT; NONHUMAN; PH; SOLID STATE; STEREOSPECIFICITY; VISCOSITY; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; DOSAGE FORMS; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; ITRACONAZOLE; PHARMACEUTIC AIDS; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 77956408789     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639041003652973     Document Type: Article

References (49)

1. Breitenbach J. (2009). The Kaletra® Meltrex story: Turning scientific challenges into patient benefit, Soliqs, May 9, 2009.
2. Gao P, Morozowich W. (2006). Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. Expert Opin Drug Deliv, 3(1):97-110.
3. Gao P, Morozowich W. (2006). Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability. United States of America Patent US 7,115,565 B22006.
4. Brewster ME, Vandecruys R, Peeters J, Neeskens P, Verreck G, Loftsson T. (2008). Comparative interaction of 2-hydroxypropyl- b-cyclodextrin and sulfobutylether-b-cyclodextrin with itraconazole: Phase-solubility behavior and stabilization of supersaturated drug solutions. Eur J Pharm Sci, doi:10.1016/ j.ejps.2008.02.007.
5. Buchanan CM, Buchanan NL, Edgar KJ, Klein S, Little JL, Ramsey MG, et al. (2007). Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations. J Pharm Sci, 96(11):3100-16.
6. Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. (2002). Characterization of the interaction of 2-hydroxypropyl-b-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci, 91(6):1414-22.
7. Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85(10):1017-25.
8. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IGH. (1999). Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-b-cyclodextrin oral solution or coatedpellet capsules. Mycoses 42(11-12):591-600.
9. Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, et al. (2003). Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci, 92(12):2386-98.
10. Keown P, Niese D. (1998). Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. Kidney Int, 54(3):938-44.
11. Bhardwaj V, Hariharan S, Bala I, Lamprecht A, Kumar N, Panchagnula R, et al. (2005). Pharmaceutical aspects of polymeric nanoparticles for oral drug delivery. J Biomed Nanotechnol, 1(3):235-58.
12. Jia L. (2005). Nanoparticle formulation increases oral bioavailability of poorly soluble drugs: Approaches, experimental evidences and theory. Curr Nanosci, 1(3):237-43.
13. Overhoff KA, McConville JT, Yang W, Johnston KP, Peters JI, Williams III RO. (2008). Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of Tacrolimus made by ultra-rapid freezing. Pharm Res, 25(1):167-75.
14. Vaughn JM, McConville JT, Crisp MT, Johnston KP, Williams III RO. (2006). Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies. Drug Dev Ind Pharm, 32(5):559-67.
15. Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL. (2003). Formulation of amphotericin B nanosuspension for oral administration. Int J Pharm, 254(1):73-5.
16. Yin SX, Franchini M, Chen J, Hsieh A, Jen S, Lee T, et al. (2005). Bioavailability enhancement of a COX-2 inhibitor, BMS- 347070, from a nanocrystalline dispersion prepared by spraydrying. J Pharm Sci, 94(7):1598-607.
17. Breitenbach J. (2006). Melt extrusion can bring new benefits to HIV therapy: The example of Kaletra tablets. Am J Drug Deliv, 4(2):61-4.
18. Six K, Daems T, de Hoon J, Van Hecken A, Depre M, Bouche M-P, et al. (2005). Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci, 24(2- 3):179-86.
19. Zheng X, Yang R, Zhang Y, Wang Z, Tang X, Zheng L. (2007). Part II: Bioavailability in beagle dogs of Nimodipine solid dispersions prepared by hot-melt extrusion. Drug Dev Ind Pharm, 33(7):783-9. (Pubitemid 47123804)
20. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, et al. (2003). Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm, 267(1- 2):79-91.
21. DiNunzio JC, Miller DA, Yang W, McGinity JW, Williams III RO. (2008). Amorphous compositions using concentration enhancing polymers for improved bioavailability. Mol Pharm, 5(6):968-80.
22. Kondo N, Iwao T, Hirai K, Fukuda M, Yamanouchi K, Yokoyama K, et al. (1994). Improved oral absorption of enteric coprecipitates of a poorly soluble drug. J Pharm Sci, 83(4):566-70
23. Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams III RO. (2008). Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition. Drug Dev Ind Pharm, 34(8):890-902.
24. Gad SC. (2007). Introduction: The gastrointestinal tract as barrier and as absorptive and metabolic organ. In: Gad SC, ed. Toxicology of the gastrointestinal tract. Boca Raton, FL: CRC Press, 1-34.
25. Kapp Jr RW. (2007). 2 Gastrointestinal tract as major route of pharmaceutical administration. In: Gad SC, ed. Toxicology of the gastrointestinal tract. Boca Raton, FL: CRC Press, 107-33.
26. Wagner D, Spahn-Langguth H, Hanafy A, Koggel A, Langguth P. (2001). Intestinal drug efflux: Formulation and food effects. Adv Drug Deliv Rev, 50(Suppl 1):S13-31.
27. Karalis V, Macheras P, Van Peer A, Shah VP. (2008). Bioavailability and bioequivalence: Focus on physiological factors and variability. Pharm Res, 25(8):1956-62.
28. McConnell EL, Fadda HM, Basit AW. (2008). Gut instincts: Explorations in intestinal physiology and drug delivery. Int J Pharm, 364(2):213-26.
29. Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams III RO. (2008). Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm Res, 25(6):1450-9.
30. Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, et al. (2007). Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of Celecoxib from solid oral formulations. J Pharm Sci, 96(10):2686-702.
31. Gao P, Guyton ME, Huang T, Bauer JM, Stefanski KJ, Lu Q. (2004). Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev Ind Pharm, 30(2):221-9.
32. Usui F, Maeda K, Kusai A, Nishimura K, Yamamoto K. (1997). Inhibitory effects of water-soluble polymers on precipitation of RS-8359. Int J Pharm, 154(1):59-66.
33. De Beule K, Van Gestel J. (2001). Pharmacology of itraconazole. Drugs, 61(1):27-37.
34. Willems L, van der Geest R, de Beule K. (2001). Itraconazole oral solution and intravenous formulations: A review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther, 26:159-69.
35. Quinney SK, Galinsky RE, Jiyamapa-Serna VA, Chen Y, Hamman MA, Hall SD, et al. (2008). Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug Metab Dispos, 36(6):1097-101.
36. Li L, Mathias NR, Heran CLH, Moench P, Wall DA, Smith RL. (2006). Carbopol-mediated paracellular transport enhancement in Calu-3 cell layers. J Pharm Sci, 95(2):326-35.
37. Peppas NA, Thomas BJ, McGinity J. (2009). Molecular aspects of mucoadhesive carrier development for drug delivery and improved absorption. J Biomater Sci Polym Ed, 20(1):1-20.
38. Borchard G, LeuBen HL, de Boer AG, Verhoef JC, Lehr C-M, Junginger HE. (1996). The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J Control Release, 39(2-3):131-8.
39. DiNunzio JC, Brough C, Miller DA, Williams III RO, McGinity JW. (2010). Fusion processing of itraconazole solid dispersions by KinetiSol® dispersing: A comparative study to hot melt extrusion. J Pharm Sci, 99(3):1239.
40. DiNunzio JC, Brough C, Miller DA, Williams III RO, McGinity JW. (2009). Applications of KinetiSol® dispersing for the production of plasticizer free amorphous solid dispersions. Eur J Pharm Sci, Submitted.
41. Mellaerts R, Mols R, Kayaert P, Annaert P, Van Humbeeck J, Van den Mooter G, et al. (2008). Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. Int J Pharm, 357(1-2):169-79.
42. Fukasawa M, Obara S. (2004). Molecular weight determination of hypromellose acetate succinate (HPMCAS) using size exclusion chromatography with a multi-angle laser light scattering detector. Chem Pharm Bull (Tokyo), 52(11):1391-3.
43. Vandecruys R, Peeters J, Verreck G, Brewster ME. (2007). Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int J Pharm, 342(1-2):168-75.
44. DiNunzio JC, Brough C, Hughey JR, Miller DA, Williams III RO, McGinity JW. (2010). Fusion production of solid dispersions containing heat sensitive active ingredient by hot melt extrusion and KinetiSol® dispersing. Eur J Pharm Biopharm, 74(2):340.
45. Six K, Verreck G, Peeters J, Augustijns P, Kinget R, Van den Mooter G. (2001). Characterization of glassy itraconazole: A comparative study of its molecular mobility below Tg with that of structural analogues using MTDSC. Int J Pharm, 213(1- 2):163-73.
46. Young CR, Dietzsch C, Cerea M, Farrell T, Fegely KA, Rajabi- Siahboomi A, et al. (2005). Physicochemical characterization and mechanisms of release of theophylline from melt-extruded dosage forms based on a methacrylic acid copolymer. Int J Pharm, 301(1-2):112-20.
47. Dressman JB, Thelen K, Jantratid E. (2008). Towards quantitative prediction of oral drug absorption. Clin Pharmacokinet, 47(10):655-67.
48. Dressman JB, Vertzoni M, Goumas K, Reppas C. (2007). Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev, 59(7):591-602.
49. McConnell EL, Basit AW, Murdan S. (2008). Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol, 60(1):63-70.